Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update

Liver International

Volumn 25, Issue 3, 2005, Pages 472-489

  Liaw, Yun Fan ^a   Leung, Nancy ^b   Guan, Richard ^c   Lau, George K K ^d   Merican, Ismail ^e   McCaughan, Geoff ^f   Gane, Edward ^g   Kao, Jia Horng ^h   Omata, Masao ⁱ   Chutaputti, B A ^j   Chen, D S ^j   Chien, R N ^j   Cooksley, G ^j   Han, K H ^j   Ichida, T ^j   Lai, M Y ^j   Lesmana, L ^j   Piratvisuth, T ^j   Sarin, S K ^j   Sollano, J ^j   Suh, D J ^j   Yao, G B ^j   Yeh, C T ^j   Yokosuka, O ^j   more..

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

^h NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j NONE

more..

Author keywords

Adefovir; Chronic hepatitis B; Hepatic decompensation; Interferon; Lamivudine; Liver transplantation

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; FIALURIDINE; HEPATITIS B ANTIBODY; INTERLEUKIN 12; LAMIVUDINE; LOBUCAVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; THYMOSIN; VIDARABINE; VIRUS ANTIGEN; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL ACTIVITY; CANCER CHEMOTHERAPY; CHINESE MEDICINE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; FATIGUE; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; INFECTION CONTROL; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NEUTROPENIA; OUTCOMES RESEARCH; PATHOGENESIS; PATIENT CARE; PATIENT MONITORING; PATIENT SATISFACTION; PRACTICE GUIDELINE; PREGNANCY; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; VIRUS REPLICATION;

ANTIVIRAL AGENTS; ASIA; AUSTRALIA; HEPATITIS B, CHRONIC; HUMANS; NEW ZEALAND; PACIFIC ISLANDS; PRACTICE GUIDELINES;

EID: 20444363583     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01134.x     Document Type: Review

References (161)

1. Liaw Y F, Leung N, Guan R, Lau G K K, Merican I, for the Asian Pacific Consensus working parties on hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003; 18: 239-45.
2. EASL J u r y. EASL international consensus conference on hepatitis B: consensus statement. J Hepatol 2003; 38: 533-40.
3. Lok A S F, McMahon B J. Chronic hepatitis B: update of recommendation. Hepatology 2004; 39: 857-61.
4. Summers J, Mason W S. Replication of the genome of a hepatitis B - like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-15.
5. Yokosuka O, Omata M, Imazeki F, Ito Y, Okuda K. Hepatitis B virus RNA transcripts and DNA in chronic liver disease. N Engl J Med 1986; 315: 1187-92.
6. Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 1985; 5: 728-34.
7. Liaw Y F. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003; 18: 246-52.
8. Hsu Y S, Chien R N, Yeh C T, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
9. Chu C M, Hung S J, Lin J, Tai D I, Liaw Y F. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-34.
10. Lai M Y, Chen D S, Lee S C, Su I J, Yang P M, Hsu H C, Sung J L. Reactivation of hepatitis B virus in anti-HBe-positive chronic active type B hepatitis: molecular and immunohistochemical studies. Hepatogastroenterology 1988; 35: 17-21.
11. Liaw Y F, Tai D I, Chu C M, Chen T J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-6.
12. Liaw Y F, Lin D Y, Chen T J, Chu C M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9: 235-41.
13. Tsai S L, Yang P M, Lai M Y, et al. Natural history of hepatitis B surface antigen-positive cirrhosis in Taiwan: a clinicopathological study. J Gastroenterol Hepatol 1988; 3: 583-92.
14. Yu M W, Hsu F C, Sheen I S, Chu C M, Lin D Y, Chen C J, Liaw Y F. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis virus carriers. Am J Epidemiol 1997; 145: 1039-47.
15. Yang H I, Lu S N, Liaw Y F, You S L, Sun C A, Wang L Y, Hsiao C K, Chen P J, Chen D S, Chen C J, for the Taiwan community-based cancer screening project group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
16. Chen Y C, Sheen I S, Chu C M, Liaw Y F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-9.
17. Yuen M F, Wong D K, Sablon E, Tse E, Ng I O, Yuan H J, Siu C W, Sander T J, Bourne E J, Hall J G, Condreay L D, Lai C L. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39: 1694-701.
18. Kao J H. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-50.
19. Fung S K, Lok A S. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004; 40: 790-2.
20. Chu C J, Keeffe E B, Han S H, Perrillo R P, Min A D, Soldevila-Pico C, Carey W, Brown R S Jr, Luketic V A, Terrault N, Lok A S. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125: 444-51.
21. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai C L, Gish R G, Ueda R, Miyakawa Y, Mizokami M. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003; 124: 925-32.
22. Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Acharya S K, Gish R G, Kramvis A, Kew M C, Yoshihara N, Shrestha S M, Khan M, Miyakawa Y, Mizokami M. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology 2004; 40: 747-55.
23. Kao J H, Chen D S. Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. Gastroenterology 2003; 125: 1916-7.
24. Chu C J, Hussain M, Lok A S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756-62.
25. Kao J H, Chen P J, Lai M Y, Chen D S. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004; 72: 363-9.
26. Ni Y H, Chang M H, Wang K J, Hsu H Y, Chen H L, Kao J H, Chen D S. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 127: 1733-8.
27. Kao J H, Chen P J, Lai M Y, Chen D S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-9.
28. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group.. Hepatology 2001; 33: 218-23.
29. Fang Z L, Yang J, Ge X, Zhuang H, Gong J, Li R, Ling R, Harrison T J. Core promoter mutations (A 1762T and G 1764 A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China. J Med Virol 2002; 68: 33-40.
30. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, Kanda T, Fukai K, Kato M, Saisho H. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37: 19-26.
31. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hind K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001; 34: 590-4.
32. Chan H L, Hui A Y, Wong M L, Tse A M, Hung L C, Wong V W, Sung J J. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-8.
33. Thakur V, Guptan R C, Kazim S N, Malhotra V, Sarin S K. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002; 17: 165-70.
34. Guan R. Interferon monotherapy in chronic hepatitis B. J. Gastroenterol Hepatol 2000; 15(Suppl.): E34-40.
35. Liaw Y F, Lin S M, Chen T J, Chien R N, Sheen I S, Chu C M. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomised controlled trial. J Hepatol 1994; 20: 175-80.
36. Janssen H L, Gerken G, Carreno V, Marcellin P, Naoumov N V, Craxi A, Ring-Larsen H, Kitis G, van Hattum J, de Vries R A, Michielsen P P, ten Kate F J, Hop W C, Heijtink R A, Honkoop P, Schalm S W. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30: 238-43.
37. Carreno V, Marcellin P, Hadziyannis S, Salmeron J, Diago M, Kitis G E, Vafiadis I, Schalm S W, Zahm F, Manzarbeitia F, Jimenez F J, Quiroga J A. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30: 277-82.
38. Sokal R. Drug treatment of paediatric chronic hepatitis B. Paediatr Drugs 2002; 4: 361-9.
39. Yokosuka O. Role of steroid priming in the treatment of chronic hepatitis B. J Gastroenterol Hepatol 2000; 13(Suppl.): E41-5.
40. Perillo R P. Chronic hepatitis B problem patients (including patients with decompensated disease). J Hepatology 1995; 22(Suppl.): 45-8.
41. Niederau C, Heintges T, Lange S, Goldmann G, Niederau C M, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.
42. Lin S M, Tai D I, Chien R N, Sheen I S, Chu C M, Liaw Y F. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat 2004; 11: 349-57.
43. van Zonneveld M, Honkoop P, Hansen B E, Niesters H G, Murad S D, de Man R A, Schalm S W, Janssen H L. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.
44. Manesis E K, Hadziyannis S J. Interferon alpha treatment and retreatment of hepatitis B e antigen negative chronic hepatitis B mutants. Gastroenterology 2001; 121: 101-9.
45. Lampertico P, Del Ninno E, Manzin A, et al. A randomised controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatoitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26: 1621-35.
46. Papatheododdis G V, Manesis E, Hadziyannis S J. The long term outcome of interon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-13.
47. Brunetto M R, Oliveri F, Coco B, et al. The outcome of chronic anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-70.
48. Lin C C, Wu J C, Chang T T, Huang Y H, Wang Y J, Tsay S H, Chow N H, Chang F Y, Lee S D. Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan. J Viral Hepat 2001; 8: 438-46.
49. Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 2003; 39Suppl. 1): S99-105.
50. Cooksley W G F, Piratvisuth T, Lee S D, et al. Peginterferon alpha 2a(40 kDa): an advance in the treatment of hepatitis Be antigen-positive chronic hepatitis B. J Viral Hepatitis 2003; 10: 298-305.
51. Janssen H L A, van Zonneveld M, Senturk H, Zeuzem S, Akarca U S, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
52. Lau G K K, Piratvisuth T, Luo K X, et al. Peginterferon alfa-2A (40KD) (Pegasys®) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study. Hepatology 2004; 40(Suppl. 1): 171A.
53. Marcellin P, Lau GKK Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg negative chronic hepatitis B. N Engl. J Med 2004; 351: 1206-17.
54. Kao J H, Wu N H, Chen P J, Lai M Y, Chen D S. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
55. Wai C T, Chu C J, Hussain M, Lok A S. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-30.
56. Schalm S W, Heathcote H, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trail. Gut 2000; 46: 562-8.
57. Barbaro G, Zechini F, Pellicelli M, et al. Long term efficacy of interferon alpha 2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicentre, randomised trial. J Hepatol 2001; 35: 406-11.
58. Santantonio T, Niro G A, Sinisi E, Leandro G, Insalata M, Guastadisegni A, Facciorusso D, Gravinese E, Andriulli A, Pastore G. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002; 36: 799-804.
59. Akarca U S, Ersoz G, Gunsar F, Karasu Z, Saritas E, Yuce G, Batur Y. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther 2004; 9: 325-34.
60. Rasi G, Mutchnick M G, Di Virgilio D, Sinibaldi-Vallebona P, Pierimarchi P, Colella F, Favalli C, Garaci E. Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B. J Viral Hepat 1996; 3: 191-6.
61. Saruc M, Ozden N, Turkel N, Ayhan S, Hock L M, Tuzcuoglu I, Yuceyar H. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci 2003; 92: 1386-95.
62. Cotonat T, Quiroga J A, Lopez-Alcorocho J M, Clouet R, Pardo M, Manzarbeitia F, Carreno V. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. Hepatology 2000; 31: 502-6.
63. Chan H L, Leung N W, Hui A Y, Wong V W, Liew C T, Chim A M, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Inter Med 2005; 142: 240-50.
64. Sugahara S, Ichida T. Yamagiwa S, Ishikawa T, Uehara K, Yoshida Y, Yang X H, Nomoto M, Watanabe H, Abo T, Asakura H. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol Res 2002; 24): 346-54.
65. Chien R N, Liaw Y F, Chen T C, Yeh C T, Sheen I S. Efficacy of thymosin α1 in patients with chronic type B hepatitis: a randomized controlled trial. Hepatology 1998; 27: 1383-7.
66. Chan H L, Tang J L, Tam W, Sung J J. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther 2001; 15: 1899-905.
67. Lau G K K. Use of immunomodulatory therapy (non-interferon) for the treatment of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000; 15(Suppl.): E46-52.
68. Lau G K, Nanji A, Hou J, Fong D Y, Au W S, Yuen S T, Lin M, Kung H F, Lam S K. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J Viral Hepat 2002; 9: 280-7.
69. Lau G K, Suri D, Liang R, Rigopoulou E I, Thomas M G, Mullerova I, Nanji A, Yuen S T, Williams R, Naoumov N V. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002; 122: 614-24.
70. Lai C L, Chien R N, Leung N W, Chang T T, Guan R, Tai D I, Ng K Y, Wu P C, Dent J C, Barber J, Stephenson S L, Gray D F. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. New Engl J Med 1998; 339: 61-8.
71. Dienstag J L, Schiff E R, Wright T L, Perrillo R P, Hann H W, Goodman Z, Crowther L, Condreay L D, Woessner M, Rubin M, Brown N A. Lamivudine as initial treatment for chronic hepatitis B in the United States. New Engl J Med 1999; 341: 1256-63.
72. Tassopoulos N C, Volpes R, Pastore G, Heathcote J, Buti M, Goldin R D, Hawley S, Barber J, Condreay L, Gray D F. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-96.
73. Chien R N, Liaw Y F, Atkins M, for Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770-4.
74. Perrillo R P, Lai C L, Liaw Y F, Dienstag J L, Schiff E R, Schalm S W, Heathcote E J, Brown N A, Atkins M, Woessner M, Gardner S D. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-94.
75. Jonas M M, Kelley D A, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-13.
76. Honkoop P, deMan R A, Niesters H G M, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635-9.
77. Chien R N, Liaw Y F. Short-term Lamivudine therapy in patients with chronic hepatitis B. Intervirology 2003; 46: 362-6.
78. Guan R, Lai C L, Liaw Y F, et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2001; 16(Suppl. 1): A60.
79. Liaw Y F. Results of lamivudine trials in Asia. J Hepatol 2003; 39: S111-5.
80. Lok A S, Lai C L, Leung N, Yao G B, Cui Z Y, Schiff E R, Dienstag J L, Heathcote E J, Little N R, Griffiths D A, Gardner S D, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
81. Yao G B, Cui Z Y, Wang B E, Yao J L, Zeng M D. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2004; 3: 188-93.
82. Song B C, Suh D J, Lee H C, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
83. Chien R N, Yeh C T, Tsai S L, Chu C M, Liaw Y F. The determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-73.
84. Fung S K, Wong F, Hussain M, Lok A S. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11: 432-8.
85. Villeneuve J P, Condreay L D, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-10.
86. Liaw Y F, Sung J J Y, Chow W C, Farrell G, Lee C Z, Yuen H, Tanwandee T, Tao Q M, Shue K, Keene O N, Dixon J S, Gray D F, Sabbat J, on behalf of the CALM study group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
87. Lai C L, Dienstag J, Schiff E, Leung N W, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
88. Liaw Y F, Chien R N, Yeh C T, Tsai S L, Chu C M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
89. Hadziyannis S J, Papatheodoridis G V, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-51.
90. Yeh C T, Chien R N, Chu C M, Liaw Y F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31: 1318-26.
91. Leung N W, Lai C L, Chang T T, Guan R, Lee C M, Ng K Y, Lim S G, Wu P C, Dent J C, Edmundson S, Condreay L D, Chien R N, on behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
92. Dienstag J L, Goldin R D, Heathcote E J, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
93. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio P L, Rizzetto M, Craxi A. Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-91.
94. Sung J J Y, Lai J Y, Zeuzem S, et al. A randomized double-blind Phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003; 38(Suppl. 2): 25-6.
95. Lai C L, Leung N W Y, Teo E K, et al. Results of one-year international phase IIb comparative trial of telbivudine, lamivudine and the combination, in patients with chronic hepatitis B. Hepatology 2003; 38(Suppl. 1): 262A.
96. Liaw Y F, Tsai S L, Chien R N, Yeh C T, Chu C M. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32: 604-9.
97. Sarin S K, Sandhu B S, Sharma B C, Jain M, Singh J, Malhotra V. Beneficial effects of 'lamivudine pulse' therapy in HBeAg positive patients with normal ALT. J Viral Hep 2004; 11: 552-8.
98. Marcellin P, Chang T T, Lim S G, et al. for the Adevofir Dipivoxil 437 Study Group. et al. Adefovir dipivoxil for the treatment of Hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
99. Hadziyannis S J, Tassopoulos N C, Heathcote E J et al. for the Adevofir Dipivoxil 438 Study Group. et al. Adefovir dipivoxil for the treatment of Hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
100. Hadziyannis S J, Tassopoulous N, Chang T T, et al. Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long term safety and efficacy study. J Hepatol 2004; 40Suppl. 1): A17. (Abstract 46).
101. Westland C E, Delaney IV W E, Yang H, et al. Hepatitis B virus genotype and virologic response in 694 patients in phase 3 studies of adefovir dipivoxil. Gastroenterology 2003; 125: 107-16.
102. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-7.
103. Yang H, Qi X, Das K, et al. In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation rtN236T in the HBV polymerase. J Hepatol 2004; 40(Suppl. 1): A.
104. Perrillo R, Hann H W, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
105. Perillo R, Willems B, Leung N, et al. Safety and efficacy of adding adefovir dipivoxil to lamivudine therapy in compensated chronic hepatitis B patients with YMDD variant and a reduced response to lamivudine: 2 year results. J Hepatol 2004; 40(Suppl. 1): A.
106. Peters M G, Hann H W, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudinen in patients with lamivudine-resistant chronic hepatitis B et al. Gastroenterology 2004; 126: 91-101.
107. Lim Y S, Lee H C, Chung Y W, Lee Y S, Suh D J. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivdudine resistant decompensated liver disease. J Gastroenterol Hepatol 2004; 19(Suppl.): A868.
108. Chang T T, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg (+) chronic hepatitis B: results of phase III study in nucleoside-naive patients. Hepatology 2004; 40(Suppl. 1): 193A.
109. Shouval D, Lai C L, Cheinquer H, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HbeAg(-) chronic hepatitis B: results of phase III trial. Hepatology 2004; 40(Suppl. 1): 728A.
110. Shermman M, Yurdaydin C, Soollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine refractory, HBeAg (+) chronic hepatitis B: results of phase III study. Hepatology 2004; 40(Suppl. 1): 664A.
111. Liaw Y F, Pramoolsinsap C, Leung V, George J, Merican I, Chen L, Cross A, DeHertogh D, Hindes R, the BEHoLD study group. Lamivudine-refractory chronic hepatitis B patients cane be safely switched to entecavir 1.0 mg daily without risk of ALT flare. J Gastroenterol Hepatol 2004; 19(Suppl.): A676.
112. Marcellin P, Mommeja-Marin H, Sacks S L, Lau G K, Sereni D, Bronowicki J P, Conway B, Trepo C, Blum M R, Yoo B C, Mondou E, Sorbel J, Snow A, Rousseau F, Lee H S. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40: 140-8.
113. Lee K S, Chung Y H, Lee K S, et al. A 12-week clevudine therapy showed durable antiviral activity and normalization of alanine transminase levels for 6 months after discontinuation of treatment in patients with chronic hepatitis B. Hepatology 2004; 40(Suppl. 1): 652A.
114. van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, Wiedenmann B, Berg T. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-5.
115. McCulloch M, Broffman M, Gao J, Colford J M Jr. Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trials. Am J Publ Health 2002; 92: 1619-28.
116. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G. Persistent and mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9.
117. van Zonneveld M, Nunen A B, Niesters H G M, Man R A, Schalm S W. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hep 2003; 10: 294-7.
118. Liaw Y F. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22: 1101-8.
119. Colin J F, Cazals-Hatem D, Loriot M A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-10.
120. Thio C L, Seaberg E C, Skolasky R Jr, et al. Multicenter AIDS Cohort Study: HIV-1, hepatitis B virus, and risk of liver related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-6.
121. Liaw Y F, Chien R N, Lin S M, Yeh C T, Tsai S L, Sheen I S, Chu C M. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interf Cytok Res 1997; 17: 449-52.
122. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni A P, Scioscia R, Serra G, Lai M E, Loy M, Caruso L, Desmet V, Purcell R H, Balestrieri A. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126: 1740-9.
123. Wong D K, Yim C, Naylor C D, Chen E, Sherman M, Vas S, Wanless I R, Read S, Li H, Heathcote E J. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108: 165-71.
124. Zylberberg H, Jiang J, Pialoux G, Driss F, Carnot F, Dubois F, Brechot C, Berthelot P, Pol S. Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol 1996; 20: 968-71.
125. Benhamou Y, Katlama C, Lunel F, et al. Effcets of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125: 705-12.
126. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-6.
127. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman K E. Chronic active hepatitis B exacerbations in human immunodeficiency virus infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28: 1032-5.
128. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine resistant hepatitis B virus. Lancet 2001; 358: 718-23.
129. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of long term adefovir dipivoxil for lamivudine resistant HBV in HIV infected patients. J Hepatol 2002; 36(Supp. 1): 138.
130. Benhamou Y, Bochet M, Tubiana R, et al. Tenofovir disoproxil fumarate suppresses lamivudine resistant HBV replication in patients coinfected with HIV/HBV. N Engl J Med 2003; 348: 177-8.
131. Chien R N, Lin C H, Liaw Y F. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003; 38: 322-7.
132. Kapoor D, Guptan R, Wakil S, Kazim S, Kaul R, Agarwal S, et al. Beneficial effects of lamivudine in hepatitis B virus related decompensated cirrhosis. J Hepatol 2000; 33: 308-12.
133. Yao F Y, Bass N M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301-7.
134. Perrillo R P, Wright T, Rakela J, et al. A multicentre United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424-32.
135. Hann H - W, Fontana R J, Wright T, et al. A United States compassionate use study of lamivudine treatment in non transplant candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003; 9: 49-56.
136. Fontana R J, Hann H W, Perrillo R P, Vierling J M, Wright T, Rakela J, Anschuetz G, Davis R, Gardner S D, Brown N A. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-27.
137. Hui J M, George J, Liddle C, Lin R, Samarasinghe D, Crewe E, Farrell G C. Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance. Am J Gastroenterol 2002; 97: 1003-9.
138. Schiff E R, Lai C L, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation. Hepatology 2003; 38: 1419-27.
139. Chang T T, Lim S G, Hadziyannis S, et al. Long tern safety of adfovir dipivoxil (ADV) in 10 mg once daily for chronic hepatitis B (CHB): an integrated analysis of two phase III studies (abs). J Hepatol 2003; 38(Suppl. 2): 133.
140. Lok A S F, Liang R H S, Chiu E K W, et al. Reactivation of hepatitis virus B replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-8.
141. Yeo W, Chan P K S, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. A prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
142. Cheng A L, Hsiung C A, Su I J, et al. Representing the Lymphoma Committee of Taiwan Co-operative Oncology Group (TCOG). Steroid free chemotherapy decrease risk of hepatitis B virus reactivation in HBV carriers with lymphoma. Hepatology 2003; 37: 1320-8.
143. Lau G K K, He M L, Fong D Y T, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702-9.
144. Chan T M, Fang G X, Tang C S O, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246-52.
145. Rossi G, Pelizzari A, Motta M, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Hematol 2001; 115: 58-62.
146. Lau G K, Yiu H H, Fong D Y, Cheng H C, Au W Y, Lai L S, Cheung M, Zhang H Y, Lie A, Ngan R, Liang R. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-9.
147. Yeo W, Chan P K, Ho W M, Zee B, Lam K C, Lei K I, Chan A T, Mok T S, Lee J J, Leung T W, Zhong S, Johnson P J. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-34.
148. Australian and New Zealand Liver Transplant Registry 13th Report. 2001 (http://www.cs.nsw.gov.au/Gastro/LiverTransplant/default.htm)
149. Levy M, Jennings L, Abouljoud M, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintman G. Quality of life improvements at 1, 2 and 5 years after liver transplantation. Transplantation 1995; 59: 515-8.
150. Armenti V, Herrine S, Radomski J. Pregnancy after liver transplantation. Liver Transpl 2000; 6: 671-85.
151. Dusheiko G M, Roberts J A. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22: 1863-73.
152. O'Grady J G. Clinical economics review: liver transplantation. Aliment Pharmacol Ther 1997; 11: 445-51.
153. Burroughs A, Blake J, Thorne S, Else M, Rolles K. Comparative hospital costs of liver transplantation and the treatment of complications of cirrhosis. Eur J Gastrol 1992; 4: 123-8.
154. Villamil F G. Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. J Hepatol 2003; 39: 466-74.
155. Lo C, Fung J, Lau G, Liu C, Cheung S, Lai C, Fan S, Wong J. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37: 36-43.
156. Bienzle U, Günther M, Neuhaus R, Vandepapeliere P, Vollmar L u n A, Neuhaus P. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003; 38: 811-9.
157. Sharma P, McQuaid K, Dent J, Fennerty M B, Sampliner R, Spechler S, Cameron A, Corley D, Falk G, Goldblum J, Hunter J, Jankowski J, Lundell L, Reid B, Shaheen N J, Sonnenberg A, Wang K, Weinstein W; AGA Chicago Workshop. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 310-30.
158. Lin D Y, Liaw Y F. Optimal surveillance of hepatocellular carcinoma in patients with chronic viral hepatitis. J Gastroenterol Hepatol 2001; 16: 715-7.
159. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300-6.
160. Liaw Y F, Chien R N, Yeh C T. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9: 257-62.
161. Wong V W, Chan H L, Wong M L, Tam J S, Leung N W. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther 2004; 19: 323-9.